Clomid and Thin Uterine Lining in PCOS: How Often, and Does It Matter?

Does Clomid Actually Thin the Uterine Lining?

Yes, and the effect shows up consistently across dozens of trials, not just in isolated case reports. Clomid’s mechanism at the hypothalamus — blocking estrogen receptors to drive up FSH — is the same mechanism that works against it at the endometrium: the drug cannot tell the difference between the estrogen receptors it needs to block in the brain and the ones lining the uterus, so both get blocked for the length of the course. A 2018 systematic review pooling 15 randomized trials and 1,957 women with WHO group II anovulation — the classification that covers most PCOS-driven anovulatory infertility — found mid-cycle endometrial thickness measurably lower on clomiphene than on letrozole. A larger 2024 meta-analysis restricted specifically to women diagnosed with PCOS, pooling 50 randomized trials, found the same direction of effect. This page exists to answer the two questions that mechanism alone doesn’t: how many millimetres, and whether it actually changes the odds of a pregnancy.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same drug, same effect on the lining — only the label for the underlying condition changed. This article uses PCOS, since that is still the term most readers search.

How Many Millimetres Thinner, in Named Trials?

The gap runs from just over one millimetre in pooled data to roughly 1.5mm in individual trials, depending on the population and how the comparison is measured. The 2018 review above found clomiphene’s mid-cycle lining averaged 1.39mm thinner than letrozole’s (95% CI: 0.51–2.27mm thinner), pooled across 3,892 treatment cycles. Named trials that measured this directly, rather than pooling across studies, put concrete numbers on that gap.

Two things are worth noticing in that table beyond the headline gap. First, the heterogeneity figures (I²) are enormous — 100% and 97.7% — which means individual trials disagreed with each other far more than they agreed on the exact size of the effect; a pooled average is real, but it describes a population trend, not a number any one cycle will hit. Second, a 2020 retrospective study of 323 women with PCOS found the same gap using a live clinical dataset rather than a pooled estimate, and the effect persisted even in a trial restricted to women already resistant to a standard clomiphene course and repeating a higher dose — the anti-estrogenic effect on the lining didn’t disappear just because the dose went up.

How Often Does the Lining Actually Fall Below a Working Threshold?

In one small trial, roughly one in seven treated cycles produced a lining under 6mm on the day of ovulation. A 2012 crossover study of 56 women taking clomiphene 100mg daily found a lining thinner than 6mm in 15.2% of cycles on ovulation day, falling to 5.1% of cycles by the seventh day after ovulation as the lining continued to build. That population is worth stating precisely: these were women with unexplained infertility, not a PCOS diagnosis — the study’s own exclusion criteria screened out endocrine disorders and a BMI over 30, which rules out most PCOS phenotypes. The number transfers usefully because it’s the identical drug, at the identical standard dose, working through the same receptor-blocking mechanism — but it is not a PCOS-specific incidence figure, and no trial in women diagnosed with PCOS has published an equivalent below-threshold frequency to confirm the rate is the same in that population.

Does a Thinner Lining Actually Lower Pregnancy Rates?

This is where the published clomid coverage on this site stops, and where the evidence itself gets genuinely equivocal rather than simply unfavorable to clomiphene. The same 2018 review that measured the 1.39mm gap also pooled pregnancy and live-birth outcomes across the identical 15 trials — and found both lower with clomiphene, even though ovulation rates themselves were not significantly different between the two drugs.

The pattern across all three sources points the same direction — but the 2018 review’s own authors were explicit that the direction of an effect is not proof of what caused it: “whether the lower [endometrial thickness] caused the lower pregnancy and live birth rates remains to be elucidated,” and they rated the overall certainty of that evidence as very low, largely because of the I² = 100% heterogeneity in the underlying trials. A thinner lining and a lower pregnancy rate showing up together across the same 15 trials is a real, repeated finding. It is not, on the evidence published so far, a demonstrated cause and effect — clomiphene’s anti-estrogenic action on cervical mucus, and possible differences in the populations that ended up in each trial arm, are both plausible alternative or contributing explanations that the pooled data can’t rule out.

How Does Letrozole Compare, in the Same Trials?

Letrozole does not carry clomiphene’s anti-estrogenic load on the endometrium, because it works through a different receptor system entirely — it lowers estrogen production upstream, at the enzyme that makes it, rather than blocking the estrogen receptors the lining itself depends on to grow. That mechanistic difference is the reason every trial in the tables above found a thicker lining on letrozole without exception, and it’s a large part of why the 2023 international guideline now names letrozole the first-choice ovulation-induction drug for PCOS rather than clomiphene. None of that is a suggestion to request a switch — it’s a report of what the trials measured, and letrozole’s own dosing and cycle-by-cycle success rates are covered on their own, separate from this comparison. Which drug is appropriate for a given cycle depends on prior response, availability, and factors a monitoring clinician weighs directly, not on a reader matching herself to a trial average.

Where This Data Does Not Settle Anything

Three limits are worth stating plainly rather than smoothing over. First, “WHO group II anovulation” and “PCOS” are not perfectly interchangeable — the 2018 review’s population is broader than a strict Rotterdam-criteria PCOS diagnosis, even though PCOS accounts for most of it, and the 2012 frequency study above excluded PCOS phenotypes entirely by design. Second, the heterogeneity in every pooled estimate here (I² = 100% and I² = 97.7%) means the “average” millimetre gap masks trials that found much bigger differences and others that found almost none — a single trial or a single cycle can reasonably land anywhere in that range. Third, no trial cited here establishes a validated millimetre cutoff, specific to a PCOS diagnosis, below which a clomiphene cycle should be abandoned or switched — that threshold, if one applies to a given cycle at all, is a call made from confirming what an individual cycle actually did, not from matching a personal ultrasound number against a trial’s pooled mean.

Cycles that don’t respond as expected — whether that’s an unusually thin lining, absent ovulation, or several courses without a pregnancy — are exactly when a specialist referral moves up rather than continuing to repeat the same course independently. For the fuller picture of how clomiphene is used and monitored day to day, Clomid’s full mechanism and course structure sit outside this comparison; this page is deliberately narrow, focused on what the trials say about the lining and the outcomes tied to it. It sits alongside the rest of the site’s fertility coverage on ovulation induction, monitoring, and what realistic odds look like once treatment starts.

Common questions